[Pathogenetic therapy of pulmonary tuberculosis in adolescents].

Acetylator phenotype in patients with breast cancer. Oncology (1978) 0.92

[Pulmonary tuberculosis caused by Mycobacterium tuberculosis of different genotypes]. Probl Tuberk Bolezn Legk (2003) 0.77

[Combined therapy of pulmonary tuberculosis by using recombinant interleukins]. Probl Tuberk Bolezn Legk (2003) 0.77

Activity of N-acetyltransferase in patients with malignant lymphomas. Neoplasma (1978) 0.77

[Role of Helicobacter pylori in the etiology of duodenal ulcer recurrence after selective proximal vagotomy]. Khirurgiia (Mosk) (1996) 0.76

[Drug sensitivity in Mycobacterium tuberculosis versus its viability, cytotoxicity, genotype, and the course of the process in patients with pulmonary tuberculosis]. Probl Tuberk Bolezn Legk (2008) 0.76

[In vitro activity of a new glycopeptide antibiotic eremomycin in relation to obligate anaerobic Gram-positive bacteria]. Antibiot Khimioter (1991) 0.76

[Methods of pathogenetic influence in combined therapy of pulmonary tuberculosis patients]. Probl Tuberk (1987) 0.75

[Monitoring of chemotherapy in patients with pulmonary tuberculosis by the blood bacteriostatic activity-determining test]. Probl Tuberk Bolezn Legk (2008) 0.75

[Complications of non-clostridial anaerobic peritonitis]. Vestn Khir Im I I Grek (1988) 0.75

[Antibiotic prophylaxis and reconstructive operations in patients with burn sequelae]. Antibiot Khimioter (1994) 0.75

[The effect of tuberculin therapy on immunologic indicators in adolescents with pulmonary tuberculosis]. Probl Tuberk (1991) 0.75

[Microflora of purulent necrotic leisions of the foot in patients with diabetes mellitus]. Antibiot Khimioter (1995) 0.75

[Clinical course of arterial hypertension in young subjects with vibration disease]. Klin Med (Mosk) (2009) 0.75

[Hepatotropic therapy in treatment of liver injury]. Antibiot Khimioter (2012) 0.75

[A case of drug-induced recurrent cholestatic hepatitis]. Ter Arkh (1989) 0.75

[Characterization of a panel of mouse single-chain antibodies against recombinant human interferon beta1b]. Tsitol Genet (2009) 0.75

[Substantiation and varieties of complex surgical treatment tactics for pyo-necrotic forms of diabetic foot]. Khirurgiia (Mosk) (1999) 0.75

Effects of hydroxypyridine derivatives mexidol and emoxypin on the reparative processes in rabbit eye on the models of corneal epithelial defect and conjunctival ischemia. Bull Exp Biol Med (2015) 0.75

[Comparative efficacy of clinical use of reamberin, remaxol and ademethionine in patients with tuberculosis of the respiratory organs and liver drug-injury]. Antibiot Khimioter (2013) 0.75

[Carboxy mimetic derivatives of nucleic acid polymeric backbones inhibiting human cytomegalovirus. 1. In vitro microbicidal effect]. Antibiot Khimioter (2007) 0.75

[Therapy strategy in the treatment of patients with drug-resistant pulmonary tuberculosis]. Probl Tuberk Bolezn Legk (2003) 0.75

[Role of a comprehensive genetic prognosis in the treatment and prevention of respiratory tuberculosis in adolescents]. Probl Tuberk Bolezn Legk (2005) 0.75

[Results of clinical and laboratory studies of anaerobic non-clostridial infection in a surgical clinic]. Vestn Ross Akad Med Nauk (1996) 0.75

[Types of immunograms in new cases of pulmonary tuberculosis]. Probl Tuberk (1989) 0.75

[Antioxidants in the combined therapy of patients with chronic destructive pulmonary tuberculosis]. Ter Arkh (1994) 0.75

[Clinical and X-ray characteristics of progressive tuberculosis in teenagers]. Probl Tuberk (1999) 0.75

[Comparative effectiveness of etiopathogenetic therapy in adolescents with destructive pulmonary tuberculosis]. Probl Tuberk (1994) 0.75

[Antimicrobial drug susceptibility of 365 Streptococcus agalactiae strains isolated in 1999-2006]. Antibiot Khimioter (2007) 0.75

[Nonclostridial obligate anaerobes--the main causative agents of lung abscesses]. Zh Mikrobiol Epidemiol Immunobiol (1987) 0.75

[Blood bacteriostatic activity in patients with respiratory tuberculosis]. Probl Tuberk (2001) 0.75

[Characteristics of endogenous intoxication of adolescents with tuberculosis]. Probl Tuberk (2002) 0.75

[Obligate anaerobic non-sporulating microflora in pleural empyema]. Sov Med (1991) 0.75

[Clinico-roentgenological characteristics of tuberculosis in adolescents]. Probl Tuberk (1985) 0.75

[The course of pulmonary tuberculosis in adolescents]. Probl Tuberk (1994) 0.75

[Empirical antibiotic therapy of wounds complicated by anaerobic non-clostridial infection]. Antibiot Khimioter (1989) 0.75

[The clinical laboratory comparison in the assessment of treatment prognosis in patients with infiltrative tuberculosis of lungs]. Klin Lab Diagn (2012) 0.75

[Combined use of tuberculin and hydrocortisone in the complex treatment of pulmonary tuberculosis]. Probl Tuberk (1991) 0.75

[Steroid hormone excretion in rats with persistent estrus]. Vopr Onkol (1970) 0.75

[The activity of alpha2-macroglobulin and its forms in patients with destructive pulmonary tuberculosis]. Probl Tuberk Bolezn Legk (2004) 0.75

[Healthcare at water transport]. Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med (2005) 0.75

[Clinical and laboratory study of cefodizime (Modivid) in prophylaxis and treatment of surgical patients]. Antibiot Khimioter (1998) 0.75

[Antiviral activity of polycarboxylic substances modified by cage hydrocarbon and sulfoacid pharmacophors against cytomegalovirus infection in vitro]. Antibiot Khimioter (2008) 0.75

[T-activin in the complex treatment of patients with pulmonary tuberculosis]. Probl Tuberk (1986) 0.75

[A role of the HLA-DRB1* genotype in the complex therapy of pulmonary tuberculosis]. Probl Tuberk Bolezn Legk (2008) 0.75

[Laboratory and clinical study of nitazole]. Antibiot Khimioter (1998) 0.75

[Approach to diagnosing tuberculosis of intrathoracic lymph nodes of a paraaortic group in children]. Probl Tuberk Bolezn Legk (2007) 0.75

[Immunogenetic aspects of the course and treatment of pulmonary tuberculosis]. Probl Tuberk Bolezn Legk (2008) 0.75

[Non-clostridial anaerobic infection in suppurative cholangitis and cholangitic abscesses of the liver]. Klin Khir (1987) 0.75

[Peculiarities of the circulating phagocytes functional activity in patients with different forms of drug-resistant pulmonary tuberculosis]. Biomed Khim (2013) 0.75

[Hormone changes and localization of tumors in rats with persistent estrus]. Vopr Onkol (1972) 0.75

In silico analysis of the structure of variable domains of mouse single-chain antibodies specific to the human recombinant interferon beta1b. Tsitol Genet (2009) 0.75

[Preclinical and clinical trials of the new tuberculosis drug perchlozon]. Ter Arkh (2016) 0.75

[Construction and characterization of immune combinatorial cDNA library of mouse variable immunoglobuline genes]. Tsitol Genet (2008) 0.75

[Experience in the use of vessel due F (sulodexide) in patients with suppurative-necrotic forms of diabetic foot without critical ischemia]. Ter Arkh (2001) 0.75

[Today's tuberculosis: the specific features of its pathogen, clinical picture, and treatment]. Probl Tuberk Bolezn Legk (2005) 0.75

[Characteristics of wound infection in long-term crush syndrome]. Khirurgiia (Mosk) (1990) 0.75

[Effects of novel antiviral agents on HIV-1 replication]. Vopr Virusol (2009) 0.75

[Localization of human cytomegalovirus immediate-early protein IE-1 pp72 in the juxtanuclear inclusion at the late stage of infection]. Vopr Virusol (2009) 0.75

[Use of different regimes of etiopathogenetic therapy in pulmonary tuberculosis in adolescents]. Probl Tuberk (1995) 0.75

[Obtaining of ScFv-CBD fusion protein and its application for affinity purification of recombinant human interferon alpha2b]. Ukr Biokhim Zh (1999) (2006) 0.75

[Perioperative management of focal liver diseases by ofloxacin]. Antibiot Khimioter (2002) 0.75

[Overproduction of single-chain antibodies against human IFN-alpha2B in Escherichia coli and their isolation in biologically active form]. Ukr Biokhim Zh (1999) (2006) 0.75

[Etiopathogenetic therapy in adolescent patients with drug-resistant Mycobacterium tuberculosis in respiratory tuberculosis]. Probl Tuberk Bolezn Legk (2004) 0.75

[Study of steroid estrogens in their AZO compound forms by thin-layer chromatography on silica gels]. Probl Endokrinol (Mosk) (1969) 0.75

[Antimicrobial chemotherapy in patients with pyo-septic diseases in intensive care units]. Khirurgiia (Mosk) (1999) 0.75

[Diagnostic and prognostic significance of some parameters of nonspecific defense humoral mechanism in patients with lymphedema complicated by erysipelas inflammation]. Klin Med (Mosk) (1998) 0.75

[The results of a multicenter study of the comparative activity of cefepime and other antibiotics against the causative agents of severe hospital infections (the Micromax program)]. Antibiot Khimioter (1999) 0.75

[Influence of membrane-active polyanions on various stages of the human cytomegalovirus life cycle in vitro]. Antibiot Khimioter (2008) 0.75